• news.cision.com/
  • Navamedic ASA/
  • Navamedic ASA (“Navamedic”, OSE: NAVA) announces it has won the tender for certain antibiotics to the Norwegian hospital market

Navamedic ASA (“Navamedic”, OSE: NAVA) announces it has won the tender for certain antibiotics to the Norwegian hospital market

Report this content

As announced on 4 August 2020, Navamedic completed the acquisition of the marketing authorisations in the Nordics for a portfolio of antibiotics for intravenous injection or infusion in a hospital setting with an annual turnover of approximately NOK 25 million.

Antibiotics for hospital use are in the Nordics mostly purchased through national or regional tenders, wherein suppliers of the products compete to win the entire supply for periods of two years. The decision is based upon a set of pre-defined criteria including price, product characteristics, user friendliness, security of supply, and environmental aspects. The environmental aspects have been given increasing importance over the last years.

Navamedic is pleased to announce that it has won the tender for the entire Norwegian market for four major antibiotics for the period from February 2022 to February 2024. The winning factors were environmental aspects and user friendliness. This tender will secure a substantial amount of the projected sales volumes for the Navamedic antibiotics portfolio through 2023.

“We are pleased to win our first antibiotics tender and delighted to see that our focus on environmental aspects and user friendliness has paid off,” says Kathrine Gamborg Andreassen, CEO of Navamedic. “Together with our partner and shareholder, ACS Dobfar, we have invested in state-of-the-art environmental documentation and user friendly packaging”.

For more information, please contact:
Kathrine Gamborg Andreassen, CEO of Navamedic ASA

+47 951 78 680          kathrine@navamedic.com

Alexander Lidmejer, Commercial Director Specialty Pharma at Navamedic ASA
+46 70 257 99 71       alexander.lidmejer@navamedic.com

About Navamedic
Navamedic ASA is a Nordic pharma company and reliable provider of high-quality products, delivered to hospitals and through pharmacies, meeting the specific needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com